Prothena Looks at Business Options as Phase III AL Amyloidosis Trial Fails
Prothena has already discontinued the development of birtamimab, and anticipates further spending cuts, including workforce reduction.
Prothena Looks at Business Options as Phase III AL Amyloidosis Trial Fails Read More »
